Collegium Pharmaceutical, Inc. COLL Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 60.7%+1.3pp | 59.3%+2.1pp | 57.2%+0.5pp | 56.7%-1.0pp | 57.7%-2.1pp | |
| Operating margin | 23.7%+0.7pp | 23%+2.3pp | 20.7%+2.4pp | 18.4%-3.0pp | 21.4%-5.5pp | |
| Net margin | 9.4%+1.4pp | 8.1%+0.3pp | 7.7%+2.6pp | 5.1%-1.5pp | 6.6%-4.3pp | |
| EBITDA margin | 31.1%+0.5pp | 30.7%-5.3pp | 36%-4.5pp | 40.4%-9.6pp | 50%-3.7pp | |
| Free cash flow margin | 41.4%-0.5pp | 42%+3.8pp | 38.2%+8.4pp | 29.9%-1.1pp | 31%-2.7pp | |
| Returns | ||||||
| Return on equity | 27.4%+3.7pp | 23.7%+0.7pp | 23%+6.8pp | 16.2%-3.1pp | 19.2%-13.4pp | |
| Return on assets | 4.6%+0.8pp | 3.8%+0.2pp | 3.6%+0.9pp | 2.7%-0.5pp | 3.2%-1.7pp | |
| Return on invested capital | 172.1%+46.5pp | 125.6%— | —— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.5×0.0× | 0.5×0.0× | 0.5×-0.1× | 0.5×+0.1× | 0.5×0.0× | |
| Inventory turnover | 13.3×+0.5× | 12.8×+4.3× | 8.5×-0.8× | 9.3×+1.1× | 8.2×+0.7× | |
| Liquidity | ||||||
| Current ratio | 1.7×+0.1× | 1.6×+0.2× | 1.4×+0.2× | 1.2×+0.1× | 1.1×+0.1× | |
| Quick ratio | 1.7×+0.2× | 1.5×+0.3× | 1.3×+0.2× | 1.1×+0.1× | 1×+0.1× | |
| Cash ratio | 0.7×+0.1× | 0.6×+0.2× | 0.3×+0.1× | 0.3×0.0× | 0.2×+0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Net debt / EBITDA | -1.1×-0.1× | -1×-0.5× | -0.5×-0.1× | -0.4×-0.1× | -0.3×-0.1× | |
| Interest coverage | 2.4×+0.3× | 2.2×+0.3× | 1.8×+0.3× | 1.6×-0.3× | 1.8×-0.5× | |
| Per Share | ||||||
| Book value per share | $7.80+3.6% | $7.53+8.0% | $6.97+17.3% | $5.94-16.8% | $7.14+25.1% | |
| Valuation | ||||||
| Market capitalization | $1.13B+17.9% | $1.46B+32.8% | $1.1B+13.9% | $967.8M+0.9% | $959.13M+3.8% | |
| Enterprise value | $845.67M-0.3% | $1.22B+27.0% | $958.04M+11.8% | $856.64M+1.0% | $848.54M+1.7% | |
| Price / earnings | 15.1×-6.8× | 23.3×+4.4× | 18.9×-7.8× | 26.7×+4.8× | 21.9×+8.5× | |
| Price / sales | 1.4×0.0× | 1.9×+0.4× | 1.5×+0.1× | 1.4×-0.1× | 1.4×0.0× | |
| Price / book | 3.6×-0.5× | 4.9×+0.8× | 4×-0.2× | 4.2×+0.1× | 4.1×+0.1× | |
| EV / EBITDA | 3.4×+0.9× | 5.1×+1.6× | 3.5×+0.5× | 3×+0.4× | 2.6×+0.1× | |
| EV / sales | 1.1×-0.2× | 1.6×+0.3× | 1.3×+0.1× | 1.2×-0.1× | 1.3×0.0× | |
| Free cash flow yield | 29.2%+7.7pp | 22.4%-3.9pp | 26.2%+4.4pp | 21.8%+0.3pp | 21.5%-1.5pp | |
| Earnings yield | 6.6%+2.1pp | 4.3%-1.0pp | 5.3%+1.6pp | 3.7%-0.8pp | 4.6%-2.9pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Collegium Pharmaceutical, Inc.'s profit margins?
- Collegium Pharmaceutical, Inc. (COLL) runs a 60.7% gross margin and a 23.7% operating margin, with a 9.4% net margin.
- Where do Collegium Pharmaceutical, Inc.'s ratios come from?
- Every ratio is computed from Collegium Pharmaceutical, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
